{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:42:29Z","timestamp":1760532149220,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejps.2021.105791","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T18:13:10Z","timestamp":1615140790000},"page":"105791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of the In-Vitro Dissolution Permeation Systems 1 (IDAS1) as a potential tool to monitor for unexpected changes in generic medicaments in poorly regulated markets"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-2873","authenticated-orcid":false,"given":"Nelson","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-4167","authenticated-orcid":false,"given":"Blanca","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginna","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilma A.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-1627","authenticated-orcid":false,"given":"Ismael J.","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl. 1","key":"10.1016\/j.ejps.2021.105791_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000175050","article-title":"Pharmacokinetics and pharmacodynamics of amlodipine","volume":"80","author":"Abernethy","year":"1992","journal-title":"Cardiology"},{"key":"10.1016\/j.ejps.2021.105791_bib0048","unstructured":"Almanza, C., N\u00fa\u00f1ez, E., 2014. MP Oficializa que muerte de neonates fue a causa de heparina. La Prensa [Panama], 6 June."},{"key":"10.1016\/j.ejps.2021.105791_bib0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpharm.2015.01.028","article-title":"Biorelevant media resistant co-culture model mimicking permeability of human intestine","volume":"481","author":"Antoine","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105791_bib0038","unstructured":"Biopharmaceutics Classification System (BCS). 2020 Therapeutic System Research Laboratories (TSRL inc.) Available at: http:\/\/www.tsrlinc.com\/services\/bcs\/search.cfm."},{"key":"10.1016\/j.ejps.2021.105791_bib0047","unstructured":"Bogdanich, W., Hooker, J., 2007. From China to Panama, a trail of poisoned medicine. The New York Times, 6 May."},{"key":"10.1016\/j.ejps.2021.105791_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/jps.21576","article-title":"IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution\/permeation system","volume":"98","author":"Buch","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0003","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40271-013-0042-z","article-title":"Patient perceptions of generic medicines: A mixed-methods study","volume":"7","author":"Dunne","year":"2014","journal-title":"Patient"},{"key":"10.1016\/j.ejps.2021.105791_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-015-0415-3","article-title":"What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs","volume":"13","author":"Dunne","year":"2015","journal-title":"BMC Medicine"},{"key":"10.1016\/j.ejps.2021.105791_bib0045","article-title":"Dirty Medicine","author":"Eban","year":"2013","journal-title":"CNN Money"},{"key":"10.1016\/j.ejps.2021.105791_bib0011","unstructured":"Eban, K., 2013. The epic inside story of long-term criminal fraud at Ranbaxy, the Indian drug company that makes generic Lipitor for millions of Americans. CNNMoney, May 15."},{"key":"10.1016\/j.ejps.2021.105791_bib0012","unstructured":"FDA Warns drugmakers in Japan, India, and China on manufacturing issues. Pharmaceutical Science Update. AAPS Newsmagazine, April 2017, p. 8."},{"key":"10.1016\/j.ejps.2021.105791_bib0014","unstructured":"FDA warns Texas drugmaker about manufacturing violations. Pharmaceutical Science Update. AAPS Newsmagazine, September 2016, p. 8."},{"key":"10.1016\/j.ejps.2021.105791_bib0042","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejpb.2019.05.020","article-title":"Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs","volume":"141","author":"Flanagan","year":"2019","journal-title":"Eur. J. Pharmaceut. Biopharm."},{"key":"10.1016\/j.ejps.2021.105791_bib0033","first-page":"581","article-title":"Dissolution\/permeation: The importance of the experimental setup for the prediction of formulation effects on fenofibrate in vivo performance","volume":"10","author":"Forner","year":"2017","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejps.2021.105791_bib0049","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1211\/jpp.60.12.0003","article-title":"Physicochemical interactions between drugs and superdisintegrants","volume":"60","author":"Fransen","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105791_bib0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","article-title":"Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: Impact on bioequivalence","volume":"65","author":"Garcia-Arieta","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/ps010203","article-title":"Prediction of dissolution-absorption relationships from a continuous dossolution\/Caco-2 system","volume":"1","author":"Ginski","year":"1999","journal-title":"AAPS Pharmsci"},{"key":"10.1016\/j.ejps.2021.105791_bib0046","unstructured":"Harris, G., 2014. Medicines made in India set off safety Worries. The New York Times, 15 Feb."},{"key":"10.1016\/j.ejps.2021.105791_bib0032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2015.05.023","article-title":"Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential","volume":"77","author":"Hens","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0008","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yebeh.2012.12.029","article-title":"Generic substitution of antiepileptic drugs- A survey of patients\u2019 perspectives in Germany and other German-speaking countries","volume":"27","author":"Hensler","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejps.2021.105791_bib0021","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0016-5085(89)80072-1","article-title":"Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model Transport System of the Intestinal Epithelium","volume":"96","author":"Hidalgo","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2021.105791_bib0031","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1021\/js960115u","article-title":"Design and evaluation of two-phase partition-dissolution method and its use in evaluating artemisinin tablets","volume":"85","author":"Hoa","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0050","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2174\/092986706778201648","article-title":"Drug Excipients","volume":"13","author":"Kal\u00e1sz","year":"2006","journal-title":"Curr. Med. Chem"},{"key":"10.1016\/j.ejps.2021.105791_bib0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Disp."},{"key":"10.1016\/j.ejps.2021.105791_bib0016","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1023\/A:1026107906191","article-title":"In vitro system to evaluate oral abs of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs","volume":"20","author":"Kataoka","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.105791_bib0025","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/jps.20691","article-title":"Effect of food intake on the oral absorption of poorly water-soluble drugs: In vitro assessment of drug dissolution and permeation assay system","volume":"95","author":"Kataoka","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0026","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejps.2011.09.007","article-title":"Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultanesou analysis of drug dissolution and permeation","volume":"44","author":"Kataoka","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0017","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s11095-011-0623-2","article-title":"Application of dissolution\/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development","volume":"29","author":"Kataoka","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.105791_bib0034","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.11.012","article-title":"An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation","volume":"82","author":"Kourentas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2019.04.003","article-title":"The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group","volume":"134","author":"Koziolek","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105791_bib0001","first-page":"923","article-title":"Analysis of Pharmacists\u2019 opinions, attitudes and experiences with generic drugs and generic substitution in the Czech Republic","volume":"70","author":"Maly","year":"2013","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.ejps.2021.105791_bib0039","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/mp200181v","article-title":"The solubility-permeability interplay: mechanistic model and predictive application of the impact of micellar solubilization on intestinal permeation","volume":"8","author":"Miller","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.105791_bib0044","article-title":"Indian-American scientists help pharma cos stay ahead in export race","author":"Mishra","year":"2013","journal-title":"The Hindu"},{"key":"10.1016\/j.ejps.2021.105791_bib0018","first-page":"23","article-title":"Innovative in vitro methodologies for establishing therapeutic equivalence","volume":"40","author":"Murray","year":"2016","journal-title":"Rev. Panam. Salud Publica"},{"key":"10.1016\/j.ejps.2021.105791_bib0006","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2012.10.032","article-title":"Generic substitution in the treatment of epilepsy: patient attitudes and perceptions","volume":"26","author":"Ngo","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejps.2021.105791_bib0030","first-page":"1","article-title":"In vitro methods to assess drug precipitation in the fasted small intestine \u2013 a PEARRL review","volume":"71","author":"O'Dwyer","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105791_bib0023","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11095-012-0767-8","article-title":"Impact of excipient interactions on drug bioavailability from solid dosage forms","volume":"29","author":"Panakanti","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.105791_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yebeh.2008.09.009","article-title":"Patient perception of generic antiepileptic drugs in the Midwestern United States","volume":"14","author":"Papsdorf","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejps.2021.105791_bib0015","unstructured":"B. Partners. Modernizing Pharma Markets in Brazil and Mexico. Posted on June 1, 2012. http:\/www.bournepartners.worldpress.com\/2012\/06\/01\/modernizing-pharma-markets-in-brazil-and-mexico."},{"key":"10.1016\/j.ejps.2021.105791_bib0002","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1472-6963-12-297","article-title":"Quality of generic medicines in South Africa: perceptions versus reality- a qualitative study","volume":"12","author":"Patel","year":"2012","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.ejps.2021.105791_bib0037","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-015-0351-6","article-title":"Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models","volume":"55","author":"Peters","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.105791_bib0004","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00228-013-1539-z","article-title":"Associations between generic substitution and patients' attitudes, beliefs and experiences","volume":"69","author":"Rathe","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105791_bib0009","first-page":"122","article-title":"Latin American pharmaceutical regulatory environment- Review Article Int","volume":"3","author":"Reddy","year":"2014","journal-title":"J. Res. Pharm. Nano Sci"},{"key":"10.1016\/j.ejps.2021.105791_bib0036","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1124\/dmd.118.082784","article-title":"Physiologically Relevant, Humanized Intestinal Systems to Study Metabolism and Transport of Small Molecule Therapeutics","volume":"46","author":"Sawant-Basak","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2021.105791_bib0019","series-title":"Essentials of Medical Pharmacology","first-page":"496","author":"Tripathi","year":"2003"},{"key":"10.1016\/j.ejps.2021.105791_bib0013","unstructured":"Two indian drugmakers hit with FDA warnings. Pharmaceutical Science Update. AAPS Newsmagazine, February 2017, p. 6."},{"key":"10.1016\/j.ejps.2021.105791_bib0022","unstructured":"US FDA Guidance for Industry, 2017. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system."},{"issue":"9 Suppl 3","key":"10.1016\/j.ejps.2021.105791_bib0041","article-title":"Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties","volume":"17","author":"van Zwieten","year":"1994","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ejps.2021.105791_bib0010","first-page":"f7507","article-title":"Escalating criminal and civic violations: Pharma has corporate integrity? Not really","volume":"347","author":"Wolfe","year":"2013","journal-title":"Br. Biomed. J."},{"key":"10.1016\/j.ejps.2021.105791_bib0027","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jps.21919","article-title":"Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes","volume":"99","author":"Yano","year":"2010","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:58:45Z","timestamp":1760529525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721000932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":50,"alternative-id":["S0928098721000932"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105791","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the In-Vitro Dissolution Permeation Systems 1 (IDAS1) as a potential tool to monitor for unexpected changes in generic medicaments in poorly regulated markets","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105791"}}